Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $36.74M |
| Gross Profit (TTM) | $-42.09M |
| EBITDA | $-66.35M |
| Operating Margin | -54.80% |
| Return on Equity | -470.40% |
| Return on Assets | -19.90% |
| Revenue/Share (TTM) | $0.55 |
| Book Value | $-1.38 |
| Price-to-Book | 2005.35 |
| Price-to-Sales (TTM) | 7.95 |
| EV/Revenue | 4.484 |
| EV/EBITDA | -1.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 112.70% |
| Shares Outstanding | $59.38M |
| Float | $28.08M |
| % Insiders | 14.13% |
| % Institutions | 76.67% |
Volatility is currently contracting
The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.28 per share a year ago.
- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027 - Accelerating a novel oral small molecule in immunology and inflammation toward IND in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $168 million ; cash runway into the first half of 2028 WATERTOWN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the second quarter ended June 30, 2026.
Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, PhD, as Non-Executive Director effective immediately. He will support the Company as it continues to advance its first-in-class CTPS1 inhibitor, dencatistat, as a treatment for essential thrombocythaemia, lymphoma and solid tumours.
Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FHTX and any ticker you trade — then tracks every position and per-strategy win rate.
